BARCELONA, Spain, Sept. 7, 2022 /CNW/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.
Read more at newswire.caGrifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/AI%20(artificial%20intelligence)/Image%20of%20server%20racks%20in%20modern%20server%20room%20data%20center%20by%20Sashkin%20via%20Shutterstock.jpg)
